You are viewing the site in preview mode
Skip to main content
|
Variable
|
OS
|
DSS
|
DMFS
|
LRFS
|
|---|
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
|---|
|
IC regimen (PF vs. TPF)
|
0.581 (0.371–0.910)
|
0.018
|
0.543 (0.343–0.859)
|
0.009
|
0.551 (0.357–0.850)
|
0.007
|
1.179 (0.667–2.084)
|
0.572
|
|
Gender (male vs. female)
|
1.166 (0.679–2.004)
|
0.578
|
1.069 (0.613–1.861)
|
0.815
|
1.065 (0.623–1.818)
|
0.819
|
0.935 (0.450–1.939)
|
0.856
|
|
Age
|
1.026 (1.006–1.046)
|
0.010
|
1.024 (1.004–1.044)
|
0.017
|
1.013 (0.994–1.033)
|
0.173
|
1.014 (0.987–1.041)
|
0.308
|
|
Smoking (yes vs. no)
|
1.020 (0.616–1.687)
|
0.939
|
1.004 (0.604–1.667)
|
0.989
|
1.118 (0.685–1.823)
|
0.656
|
1.061 (0.555–2.028)
|
0.857
|
|
T stage (T1–2 vs. T3–4)
|
1.349 (0.866–2.101)
|
0.185
|
1.345 (0.863–2.096)
|
0.191
|
1.449 (1.056–1.987)
|
0.021
|
1.434 (0.752–2.733)
|
0.274
|
|
N stage (N0–1 vs. N2–3)
|
1.285 (0.975–1.693)
|
0.075
|
1.319 (0.995–1.748)
|
0.054
|
1.652 (1.278–2.134)
|
0.001
|
1.125 (0.778–1.627)
|
0.532
|
|
Clinical stage (III vs. IV)
|
2.193 (1.419–3.390)
|
0.001
|
2.277 (1.459–3.552)
|
0.001
|
1.137 (0.663–1.042)
|
0.667
|
0.891 (0.386–2.057)
|
0.787
|
|
Radiation technique (IMRT vs. 2D-CRT)
|
1.835 (1.153–2.919)
|
0.010
|
1.859 (1.159–2.982)
|
0.010
|
2.152 (1.370–3.380)
|
0.001
|
1.089 (0.550–2.156)
|
0.807
|
- IC induction chemotherapy, TPF taxane, cisplatin and 5-fluorouracil, PF cisplatin and 5-fluorouracil, CDDP dose the cisplatin dose of concurrent chemotherapy, IMRT intensity-modulated radiotherapy, 2D-CRT two-dimensional radiotherapy, RT radiotherapy, HR hazard ratio
